摘要
目的探讨CYFRA21-1在乳腺癌中的表达情况及其临床意义。方法分别检测86例原发性乳腺癌,14例复发性乳腺癌,22例良性乳腺肿瘤,25例正常人群中血清CYFRA21-1、CEA、CA153的表达情况,并检测血清CYFRA21-1含量与临床病理特征﹑预后及无病生存时间的关系。结果乳腺良性肿瘤人群与正常人群中CYFRA21-1的差别无统计学意义。CYFRA21-1在Ⅳ期乳腺癌及复发性乳腺癌中的阳性率分别为60%和64.2%,其阳性率高于CA153和CEA。在血运性复发性乳腺癌病例中,其灵敏度较高,为89%。随着TNM分期的增加CYFRA21-1的水平逐渐升高。CYFRA21-1与CEA无统计学关联,与CA153有轻度统计学关联,单因素及多因素分析均显示:CYFRA21-1可作为判断乳腺癌预后的一个独立指标。结论检测CYFRA21-1水平对检测乳腺癌复发及评估治疗效果有非常大的价值。
Objective To study expression of serum CYFRA21-1 in breast cancers and its clinical significance.Methods The serum samples of 86 patients with primary breast carcinoma,14 patients with recurrent breast carcinoma,22 patients with benign mammary disease,and 25 healthy controls were provided for measurements of CYFRA 21-1,carcinoembryonic antigen（CEA）,and CA 15-3.The relation between clinicopathologic features,prognosis,and disease free survival with serum CYFRA 21-1 titers was studied. Results There was no difference between the serum CYFRA 21-1 titers from patients with benign mammary disease and those from healthy controls.The sensitivities of CYFRA 21-1 for patients with International Union Against Cancer Stage IV and recurrent tumors were 60%and 64.2%,respectively,which were as high as those for CA 15-3 and superior to those for CEA.The hematogenous recurrence showed a very high sensitivity of 89%.According to the increments of T,N,and M factor numbers,the serum CYFRA 21-1 titers were elevated.No correlation between CYFRA 21-1 and CEA was observed and the correlation between CYFRA 21-1 and CA 15-3 was weak.The univariate and multivariate analyses for survival revealed that serum CYFRA 21-1 levels were an independent indicator of prognosis.Conclusion The measurement of the serum CYFRA 21-1 titer in patients with breast carcinoma may be useful in monitoring for recurrence and evaluating the therapeutic effect in patients with advanced disease.
出处
《江西医药》
CAS
2010年第4期299-302,共4页
Jiangxi Medical Journal
